Stiris Research Inc. Awarded Phase II/III Trial in Hypothyroidism
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, announces the award of a phase II/III study for the treatment of Hypothyroidism.
“The successful outcome of this study will advance meaningful treatment options for individuals living with hypothyroidism, with the goal of improving long-term disease management for this chronic condition.” said Shantal Feltham, President & CEO.
Hypothyroidism is a pathological state of thyroid hormone deficiency characterized by a systemic deceleration of metabolic processes. It results from a failure at any point in the hypothalamic-pituitary-thyroid (HPT) axis, leading to insufficient levels of circulating free thyroxine (T4) and triiodothyronine (T3).
(https://www.ncbi.nlm.nih.gov/books)
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: